Novel strategy for the use of leptin for obesity therapy

Bibliography

• Bray GA, Greenway FL. Pharmacological treatment of the overweight patient. Pharmacol Rev 2007;59:151-84
   PubMed Web of Science ®Google Scholar
• Greenway FL, Bray GA. Combination drugs for treating obesity. Curr Diab Rep 2010;10:108-15
   PubMed Web of Science ®Google Scholar
• Pi-Sunyer X. The medical risks of obesity. Postgrad Med 2009;121:21-33
   PubMed Web of Science ®Google Scholar
• Weintraub M. Long-term weight control study: conclusions. Clin Pharmacol Ther 1992;51:642-6
   PubMed Web of Science ®Google Scholar
• Shimabukuro M, Koyama K, Chen G, Direct antidiabetic effect of leptin through triglyceride depletion of tissues. Proc Natl Acad Sci USA 1997;94:4637-41
   PubMed Web of Science ®Google Scholar
• Nemecz M, Preininger K, Englisch R, Acute effect of leptin on hepatic glycogenolysis and gluconeogenesis in perfused rat liver. Hepatology 1999;29:166-72
   PubMed Web of Science ®Google Scholar
• Minokoshi Y, Kahn BB. Role of AMP-activated protein kinase in leptin-induced fatty acid oxidation in muscle. Biochem Soc Trans 2003;31:196-201
   PubMed Web of Science ®Google Scholar
• Lutz TA. Amylinergic control of food intake. Physiol Behav 2006;89:465-71
   PubMed Web of Science ®Google Scholar
• Roth JD, Roland BL, Cole RL, Leptin responsiveness restored by amylin agonism in diet-induced obesity: evidence from nonclinical and clinical studies. Proc Natl Acad Sci USA 2008;105:7257-62
   PubMed Web of Science ®Google Scholar
• Trevaskis JL, Coffey T, Cole R, Amylin-mediated restoration of leptin responsiveness in diet-induced obesity: magnitude and mechanisms. Endocrinology 2008;149:5679-87
   PubMed Web of Science ®Google Scholar
• Ludvik B, Kautzky-Willer A, Prager R, Amylin: history and overview. Diabet Med 1997;14(Suppl 2):S9-13
   Google Scholar
• Juhl CB, Porksen N, Sturis J, High-frequency oscillations in circulating amylin concentrations in healthy humans. Am J Physiol Endocrinol Metab 2000;278:E484-90
   PubMed Web of Science ®Google Scholar
• Available from: http://online.factsandcomparisons.com [Accessed 9 August 2011]
   Google Scholar
• Younk LM, Mikeladze M, Davis SN. Pramlintide and the treatment of diabetes: a review of the data since its introduction. Expert Opin Pharmacother 2011;12:1439-51
   PubMed Web of Science ®Google Scholar
• Weyer C, Maggs DG, Young AA, Kolterman OG. Amylin replacement with pramlintide as an adjunct to insulin therapy in type 1 and type 2 diabetes mellitus: a physiological approach toward improved metabolic control. Curr Pharm Des 2001;7:1353-73
   PubMed Web of Science ®Google Scholar
• Montague CT, Farooqi IS, Whitehead JP, Congenital leptin deficiency is associated with severe early-onset obesity in humans. Nature 1997;387:903-8
   PubMed Web of Science ®Google Scholar
• Farooqi IS, Matarese G, Lord GM, Beneficial effects of leptin on obesity, T cell hyporesponsiveness, and neuroendocrine/metabolic dysfunction of human congenital leptin deficiency. J Clin Invest 2002;110:1093-103
   PubMed Web of Science ®Google Scholar
• Farooqi IS, Jebb SA, Langmack G, Effects of recombinant leptin therapy in a child with congenital leptin deficiency. N Engl J Med 1999;341:879-84
   PubMed Web of Science ®Google Scholar
• Galgani JE, Greenway FL, Caglayan S, Leptin replacement prevents weight loss-induced metabolic adaptation in congenital leptin-deficient patients. J Clin Endocrinol Metab 2010;95:851-5
   PubMed Web of Science ®Google Scholar
• Oral EA, Simha V, Ruiz E, Leptin-replacement therapy for lipodystrophy. N Engl J Med 2002;346:570-8
   PubMed Web of Science ®Google Scholar
• Javor ED, Ghany MG, Cochran EK, Leptin reverses nonalcoholic steatohepatitis in patients with severe lipodystrophy. Hepatology 2005;41:753-60
   PubMed Web of Science ®Google Scholar
• Welt CK, Chan JL, Bullen J, Recombinant human leptin in women with hypothalamic amenorrhea. N Engl J Med 2004;351:987-97
   PubMed Web of Science ®Google Scholar
• Chou SH, Chamberland JP, Liu X, Leptin is an effective treatment for hypothalamic amenorrhea. Proc Natl Acad Sci USA 2011;108:6585-90
   PubMed Web of Science ®Google Scholar
• Audi L, Mantzoros CS, Vidal-Puig A, Leptin in relation to resumption of menses in women with anorexia nervosa. Mol Psychiatry 1998;3:544-7
   PubMed Web of Science ®Google Scholar
• Miller KK, Parulekar MS, Schoenfeld E, Decreased leptin levels in normal weight women with hypothalamic amenorrhea: the effects of body composition and nutritional intake. J Clin Endocrinol Metab 1998;83:2309-12
   PubMed Web of Science ®Google Scholar
• Heymsfield SB, Greenberg AS, Fujioka K, Recombinant leptin for weight loss in obese and lean adults: a randomized, controlled, dose-escalation trial. JAMA 1999;282:1568-75
   PubMed Web of Science ®Google Scholar
• Leibel RL, Rosenbaum M, Hirsch J. Changes in energy expenditure resulting from altered body weight. N Engl J Med 1995;332:621-8
   PubMed Web of Science ®Google Scholar
• Lecoultre V, Ravussin E, Redman LM. The fall in leptin concentration is a major determinant of the metabolic adaptation induced by caloric restriction independently of the changes in leptin circadian rhythms. J Clin Endocrinol Metab 2011; published online July 21, 2011; doi: 10.1210/jc.2011-1286
   PubMed Web of Science ®Google Scholar
• Doucet E, Imbeault P, St-Pierre S, Greater than predicted decrease in energy expenditure during exercise after body weight loss in obese men. Clin Sci (Lond) 2003;105:89-95
   PubMed Web of Science ®Google Scholar
• Doucet E, St PS, Almeras N, Changes in energy expenditure and substrate oxidation resulting from weight loss in obese men and women: is there an important contribution of leptin? J Clin Endocrinol Metab 2000;85:1550-6
   PubMed Web of Science ®Google Scholar
• Tremblay A, Pelletier C, Doucet E, Imbeault P. Thermogenesis and weight loss in obese individuals: a primary association with organochlorine pollution. Int J Obes Relat Metab Disord 2004;28:936-9
   PubMed Web of Science ®Google Scholar
• Leibel RL. The role of leptin in the control of body weight. Nutr Rev 2002;60:S15-19
   PubMed Web of Science ®Google Scholar
• Frederich RC, Lollmann B, Hamann A, Expression of ob mRNA and its encoded protein in rodents. Impact of nutrition and obesity. J Clin Invest 1995;96:1658-63
   PubMed Web of Science ®Google Scholar
• Frederich RC, Hamann A, Anderson S, Leptin levels reflect body lipid content in mice: evidence for diet-induced resistance to leptin action. Nat Med 1995;1:1311-14
   PubMed Web of Science ®Google Scholar
• Ahima RS, Prabakaran D, Mantzoros C, Role of leptin in the neuroendocrine response to fasting. Nature 1996;382:250-2
   PubMed Web of Science ®Google Scholar
• Ravussin Y, Gutman R, Diano S, Effects of chronic weight perturbation on energy homeostasis and brain structure in mice. Am J Physiol Regul Integr Comp Physiol 2011;300:R1352-62
   Web of Science ®Google Scholar
• Rosenbaum M, Murphy EM, Heymsfield SB, Low dose leptin administration reverses effects of sustained weight-reduction on energy expenditure and circulating concentrations of thyroid hormones. J Clin Endocrinol Metab 2002;87:2391-4
   PubMed Web of Science ®Google Scholar
• Rosenbaum M, Goldsmith R, Bloomfield D, Low-dose leptin reverses skeletal muscle, autonomic, and neuroendocrine adaptations to maintenance of reduced weight. J Clin Invest 2005;115:3579-86
   PubMed Web of Science ®Google Scholar
• Shetty GK, Matarese G, Magkos F, Leptin administration to overweight and obese subjects for 6 months increases free leptin concentrations but does not alter circulating hormones of the thyroid and IGF axes during weight loss induced by a mild hypocaloric diet. Eur J Endocrinol 2011;165:249-54
   PubMed Web of Science ®Google Scholar
• Levin BE, Dunn-Meynell AA, Banks WA. Obesity-prone rats have normal blood-brain barrier transport but defective central leptin signaling before obesity onset. Am J Physiol Regul Integr Comp Physiol 2004;286:R143-50
   PubMed Web of Science ®Google Scholar
• Munzberg H, Flier JS, Bjorbaek C. Region-specific leptin resistance within the hypothalamus of diet-induced obese mice. Endocrinology 2004;145:4880-9
   PubMed Web of Science ®Google Scholar
• Trevaskis JL, Parkes DG, Roth JD. Insights into amylin-leptin synergy. Trends Endocrinol Metab 2010;21:473-9
   PubMed Web of Science ®Google Scholar
• Seth R, Knight WD, Overton JM. Combined amylin-leptin treatment lowers blood pressure and adiposity in lean and obese rats. Int J Obes (Lond) 2010; published online 21 December 2010; doi:10.1038/ijo.2010.262
   PubMed Web of Science ®Google Scholar
• Trevaskis JL, Coffey T, Cole R, Amylin-mediated restoration of leptin responsiveness in diet-induced obesity: magnitude and mechanisms. Endocrinology 2008;149:5679-87
   PubMed Web of Science ®Google Scholar
• Trevaskis JL, Lei C, Koda JE, Interaction of leptin and amylin in the long-term maintenance of weight loss in diet-induced obese rats. Obesity (Silver Spring) 2010;18:21-6
   PubMed Web of Science ®Google Scholar
• Turek VF, Trevaskis JL, Levin BE, Mechanisms of amylin/leptin synergy in rodent models. Endocrinology 2010;151:143-52
   PubMed Web of Science ®Google Scholar
• Moon HS, Matarese G, Brennan AM, Efficacy of metreleptin in obese patients with type 2 diabetes: cellular and molecular pathways underlying leptin tolerance. Diabetes 2011;60:1647-56
   PubMed Web of Science ®Google Scholar
• Ravussin E, Smith SR, Mitchell JA, Enhanced weight loss with pramlintide/metreleptin: an integrated neurohormonal approach to obesity pharmacotherapy. Obesity (Silver Spring) 2009;17:1736-43
   PubMed Web of Science ®Google Scholar
• Kolterman OG, Schwartz S, Corder C, Effect of 14 days' subcutaneous administration of the human amylin analogue, pramlintide (AC137), on an intravenous insulin challenge and response to a standard liquid meal in patients with IDDM. Diabetologia 1996;39:492-9
   PubMed Web of Science ®Google Scholar
• Colburn WA, Gottlieb AB, Koda J, Kolterman OG. Pharmacokinetics and pharmacodynamics of AC137 (25,28,29 tripro-amylin, human) after intravenous bolus and infusion doses in patients with insulin-dependent diabetes. J Clin Pharmacol 1996;36:13-24
   PubMed Web of Science ®Google Scholar
• McDuffie JR, Riggs PA, Calis KA, Effects of exogenous leptin on satiety and satiation in patients with lipodystrophy and leptin insufficiency. J Clin Endocrinol Metab 2004;89:4258-63
   PubMed Web of Science ®Google Scholar
• Moran SA, Patten N, Young JR, Changes in body composition in patients with severe lipodystrophy after leptin replacement therapy. Metabolism 2004;53:513-19
   PubMed Web of Science ®Google Scholar
• Petersen KF, Oral EA, Dufour S, Leptin reverses insulin resistance and hepatic steatosis in patients with severe lipodystrophy. J Clin Invest 2002;109:1345-50
   PubMed Web of Science ®Google Scholar
• Lee Y, Yu X, Gonzales F, PPARalpha is necessary for the lipopenic action of hyperleptinemia on white adipose and liver tissue. Proc Natl Acad Sci USA 2002;99:11848-53
   PubMed Web of Science ®Google Scholar
• Orci L, Cook WS, Ravazzola M, Rapid transformation of white adipocytes into fat-oxidizing machines. Proc Natl Acad Sci USA 2004;101:2058-63
   PubMed Web of Science ®Google Scholar
• Unger RH. Leptin physiology: a second look. Regul Pept 2000;92:87-95
   PubMed Web of Science ®Google Scholar
• Unger RH. Minireview: weapons of lean body mass destruction: the role of ectopic lipids in the metabolic syndrome. Endocrinology 2003;144:5159-65
   PubMed Web of Science ®Google Scholar
• Minokoshi Y, Kim YB, Peroni OD, Leptin stimulates fatty-acid oxidation by activating AMP-activated protein kinase. Nature 2002;415:339-43
   PubMed Web of Science ®Google Scholar
• Javor ED, Cochran EK, Musso C, Long-term efficacy of leptin replacement in patients with generalized lipodystrophy. Diabetes 2005;54:1994-2002
   PubMed Web of Science ®Google Scholar
• Park JY, Javor ED, Cochran EK, Long-term efficacy of leptin replacement in patients with Dunnigan-type familial partial lipodystrophy. Metabolism 2007;56:508-16
   PubMed Web of Science ®Google Scholar
• Chan JL, Oral EA. Clinical classification and treatment of congenital and acquired lipodystrophy. Endocr Pract 2010;16:310-23
   PubMed Web of Science ®Google Scholar
• Amylin Pharmaceuticals SDCI2M2 Investigators brochure: recombinant-methionyl leptin human metreleptin for use in studies in obese subjects when administered in conjunction with pramlintide; 2010
   Google Scholar
• Chan JL, Wong SL, Mantzoros CS. Pharmacokinetics of subcutaneous recombinant methionyl human leptin administration in healthy subjects in the fed and fasting states: regulation by gender and adiposity. Clin Pharmacokinet 2008;47:753-64
   PubMed Web of Science ®Google Scholar
• SYMLINA® (pramlintide acetate injection. San Diego, CA: Amylin Pharmaceuticals, Inc., 2010. Available from: http://documents/symlin.com/SYMLIN_PI.pdf [Last accessed 24 August 2011]
   Google Scholar
• Whitehouse F, Kruger DF, Fineman M, A randomized study and open-label extension evaluating the long-term efficacy of pramlintide as an adjunct to insulin therapy in type 1 diabetes. Diabetes Care 2002;25:724-30
   PubMed Web of Science ®Google Scholar
• Edelman S, Garg S, Frias J, A double-blind, placebo-controlled trial assessing pramlintide treatment in the setting of intensive insulin therapy in type 1 diabetes. Diabetes Care 2006;29:2189-95
   PubMed Web of Science ®Google Scholar
• Ratner RE, Dickey R, Fineman M, Amylin replacement with pramlintide as an adjunct to insulin therapy improves long-term glycaemic and weight control in Type 1 diabetes mellitus: a 1-year, randomized controlled trial. Diabet Med 2004;21:1204-12
   PubMed Web of Science ®Google Scholar
• Riddle M, Pencek R, Charenkavanich S, Randomized comparison of pramlintide or mealtime insulin added to basal insulin treatment for patients with type 2 diabetes. Diabetes Care 2009;32:1577-82
   PubMed Web of Science ®Google Scholar
• Riddle M, Frias J, Zhang B, Pramlintide improved glycemic control and reduced weight in patients with type 2 diabetes using basal insulin. Diabetes Care 2007;30:2794-9
   PubMed Web of Science ®Google Scholar
• Hollander PA, Levy P, Fineman MS, Pramlintide as an adjunct to insulin therapy improves long-term glycemic and weight control in patients with type 2 diabetes: a 1-year randomized controlled trial. Diabetes Care 2003;26:784-790
   PubMed Web of Science ®Google Scholar